title: Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity.
abstract: OBJECTIVE
  The goal of this study was to evaluate the tolerance and effectiveness of carboplatin rechallenge using a prolonged desensitizing carboplatin infusion regimen in patients with clinically documented moderate-severe carboplatin hypersensitivity.
  
  
  METHODS
  Patients admitted for carboplatin infusion were identified by computerized pharmacy records and retrospectively analyzed.
  
  
  RESULTS
  Thirty-three patients with recurrent ovarian (N = 27), peritoneal (N = 4), tubal (N = 1), and cervical (N = 1) cancer treated with a prolonged desensitizing carboplatin infusion regimen were identified. The patients had received a median of 10 courses of carboplatin (range 3-33) before developing the moderate-severe hypersensitivity reaction. Two hundred and fifteen courses (median 5, range 1-52) were administered. Twenty-nine patients (88%) were successfully rechallenged while four had a recurrent moderate-severe carboplatin hypersensitivity precluding further administration. Despite initial tolerance of the infusion schedule moderate-severe carboplatin hypersensitivity recurred in 3 additional patients (9%) after two, three, and six subsequent courses. Objective responses to therapy were seen in 22 of 28 evaluable patients (79%).
  
  
  CONCLUSIONS
  A prolonged desensitizing carboplatin infusion regimen is tolerated in the majority of patients with clinically documented moderate-severe carboplatin hypersensitivity. Objective response rates seem acceptable with this schedule.
authors.affiliation: Case Western Reserve University, Ireland Cancer Center, Cleveland, OH 44106, USA. prose@metrohealth.org
authors.forename: Peter G
authors.initials: PG
authors.lastname: Rose
authors.forename: Nancy
authors.initials: N
authors.lastname: Fusco
authors.forename: Mary
authors.initials: M
authors.lastname: Smrekar
authors.forename: Kim
authors.initials: K
authors.lastname: Mossbruger
authors.forename: Michael
authors.initials: M
authors.lastname: Rodriguez
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects*; D003888:Desensitization, Immunologic / Q000379:methods*; D004334:Drug Administration Schedule; D004342:Drug Hypersensitivity / Q000209:etiology* / Q000517:prevention & control*; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010534:Peritoneal Neoplasms / Q000188:drug therapy; D012189:Retrospective Studies; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin